JP4637481B2 - Cds1/chk2阻害剤および癌治療における化学療法または放射線療法の補助剤としての2−フェニルベンズイミダゾールおよびイミダゾ−[4,5]−ピリジン - Google Patents

Cds1/chk2阻害剤および癌治療における化学療法または放射線療法の補助剤としての2−フェニルベンズイミダゾールおよびイミダゾ−[4,5]−ピリジン Download PDF

Info

Publication number
JP4637481B2
JP4637481B2 JP2003535787A JP2003535787A JP4637481B2 JP 4637481 B2 JP4637481 B2 JP 4637481B2 JP 2003535787 A JP2003535787 A JP 2003535787A JP 2003535787 A JP2003535787 A JP 2003535787A JP 4637481 B2 JP4637481 B2 JP 4637481B2
Authority
JP
Japan
Prior art keywords
phenyl
chloro
benzimidazole
compound
carboxylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2003535787A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005506349A5 (https=
JP2005506349A (ja
Inventor
アリエンテイ,クリステン・エル
アセク,フランク・ユー
ブライテンブツチヤー,ジエイ・ガイ
ハング,リミング
リー,アリス
マクリユー,ケリー・ジエイ
Original Assignee
オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド filed Critical オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド
Publication of JP2005506349A publication Critical patent/JP2005506349A/ja
Publication of JP2005506349A5 publication Critical patent/JP2005506349A5/ja
Application granted granted Critical
Publication of JP4637481B2 publication Critical patent/JP4637481B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2003535787A 2001-10-19 2002-10-18 Cds1/chk2阻害剤および癌治療における化学療法または放射線療法の補助剤としての2−フェニルベンズイミダゾールおよびイミダゾ−[4,5]−ピリジン Expired - Lifetime JP4637481B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33030401P 2001-10-19 2001-10-19
PCT/US2002/033371 WO2003032984A1 (en) 2001-10-19 2002-10-18 2-phenyl benzimidazoles and imidazo-[4,5]-pyridines as cdsi/chk2-inhibitors and adjuvants to chemotherapy or radiation therapy in the treatment of cancer

Publications (3)

Publication Number Publication Date
JP2005506349A JP2005506349A (ja) 2005-03-03
JP2005506349A5 JP2005506349A5 (https=) 2006-01-05
JP4637481B2 true JP4637481B2 (ja) 2011-02-23

Family

ID=23289169

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003535787A Expired - Lifetime JP4637481B2 (ja) 2001-10-19 2002-10-18 Cds1/chk2阻害剤および癌治療における化学療法または放射線療法の補助剤としての2−フェニルベンズイミダゾールおよびイミダゾ−[4,5]−ピリジン

Country Status (12)

Country Link
US (2) US7271261B2 (https=)
EP (1) EP1435947B1 (https=)
JP (1) JP4637481B2 (https=)
AT (1) ATE369854T1 (https=)
BR (1) BR0206161A (https=)
CA (1) CA2464000C (https=)
DE (1) DE60221866T2 (https=)
ES (1) ES2292812T3 (https=)
NO (1) NO20032759L (https=)
RS (1) RS50939B (https=)
WO (1) WO2003032984A1 (https=)
ZA (1) ZA200305533B (https=)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003257329C1 (en) 2002-08-19 2010-07-22 Lorus Therapeutics Inc. 2,4,5-trisubstituted imidazoles and their use as anti-microbial agents
DE10243027A1 (de) * 2002-09-17 2004-03-25 Bayer Ag 2-Phenyl-benzimidazol-5-sulfonsäure aus isolierter 3,4-Diaminobenzol-sulfonsäure sowie deren Verwendung in kosmetischen Zubereitungen
JP4726235B2 (ja) 2003-04-17 2011-07-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 癌の処置のためのチェックポイントキナーゼcds1(chk2)インヒビターとしての2−フェニル−ベンズイミダゾールおよび2−フェニル−イミダゾ−‘4,5!−ピリジン誘導体
US20050078598A1 (en) * 2003-08-21 2005-04-14 Anuj Batra Enhancement to the multi-band OFDM physical layer
US8969372B2 (en) 2003-11-14 2015-03-03 Aptose Boisciences Inc. Aryl imidazoles and their use as anti-cancer agents
EP1824832B1 (en) * 2004-06-30 2011-04-27 Janssen Pharmaceutica NV Aryl-substituted benzimidazole and imidazopyridine ethers as anti-cancer agents
KR20060087386A (ko) 2005-01-28 2006-08-02 주식회사 대웅제약 신규 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물
PL1861387T3 (pl) * 2005-01-28 2014-08-29 Dae Woong Pharma Pochodne benzoimidazolu i ich kompozycje farmaceutyczne
US7534796B2 (en) 2005-02-18 2009-05-19 Wyeth Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
US7582634B2 (en) 2005-02-18 2009-09-01 Wyeth 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7538113B2 (en) 2005-02-18 2009-05-26 Wyeth 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
ES2400287T3 (es) * 2005-03-14 2013-04-08 High Point Pharmaceuticals, Llc Derivados de benzazol, composiciones y procedimientos de uso como inhibidores de beta-secretasa
US7531542B2 (en) 2005-05-18 2009-05-12 Wyeth Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
AU2006250809B2 (en) 2005-05-25 2011-05-12 Lorus Therapeutics Inc. 2-indolyl imidazo(4,5-D)phenanthroline derivatives and their use in the treatment of cancer
US7582636B2 (en) 2005-05-26 2009-09-01 Wyeth Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
US8039637B2 (en) * 2005-06-23 2011-10-18 Array Biopharma Inc. Process for preparing benzimidazole compounds
US8334290B2 (en) 2005-10-31 2012-12-18 Merck Sharp & Dohme Corp. CETP inhibitors
PT2054405E (pt) 2006-07-11 2013-12-24 Dae Woong Pharma Novos derivados de biaril benzoimidazol e composição farmacêutica que compreende os mesmos
FR2904314A1 (fr) * 2006-07-26 2008-02-01 Centre Nat Rech Scient Composes pyridaziniques et pyrroliques lineaires, procedes d'obtention et applications
AR063311A1 (es) * 2006-10-18 2009-01-21 Novartis Ag Compuestos organicos
PE20090188A1 (es) 2007-03-15 2009-03-20 Novartis Ag Compuestos heterociclicos como moduladores de la senda de hedgehog
ATE518839T1 (de) * 2007-08-23 2011-08-15 Sanofi Sa Azoloarin derivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
GB0719644D0 (en) 2007-10-05 2007-11-14 Cancer Rec Tech Ltd Therapeutic compounds and their use
CA2709203A1 (en) * 2007-12-13 2009-06-18 Siena Biotech S.P.A. Hedgehog pathway antagonists and therapeutic applications thereof
JP2009171854A (ja) * 2008-01-21 2009-08-06 Olympus Corp 細胞洗浄方法および移植物の製造方法
GB0803018D0 (en) 2008-02-19 2008-03-26 Cancer Rec Tech Ltd Therapeutic compounds and their use
EP2279177A1 (en) * 2008-04-22 2011-02-02 Merck Frosst Canada Ltd. Novel substituted heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
WO2010126743A1 (en) 2009-04-27 2010-11-04 High Point Pharmaceuticals, Llc SUBSTITUTED ISOQUINOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS β-SECRETASE INHIBITORS
WO2011119465A1 (en) 2010-03-23 2011-09-29 High Point Pharmaceuticals, Llc Substituted imidazo[1,2-b]pyridazine derivatives, pharmaceutical compositions, and methods of use as beta-secretase inhibitors
US8609672B2 (en) 2010-08-27 2013-12-17 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
JP5871933B2 (ja) * 2010-09-10 2016-03-01 バイオ−ラッド ラボラトリーズ インコーポレーティッド Dna内のrna相互作用領域の検出
AU2011308256B2 (en) * 2010-09-28 2015-08-20 Daewoong Pharmaceutical Co., Ltd. Novel method of preparing benzoimidazole derivatives
EP2675913B1 (en) 2011-02-15 2016-12-14 Bio-Rad Laboratories, Inc. Detecting methylation in a subpopulation of genomic dna
KR101387970B1 (ko) 2011-04-20 2014-04-25 인제대학교 산학협력단 암 예방 및 치료용 조성물 및 건강기능식품
RU2641693C2 (ru) 2011-11-09 2018-01-22 Кансер Ресёрч Текнолоджи Лимитед Соединения 5-(пиридин-2-иламино)-пиразин-2-карбонитрила и их терапевтическое применение
RU2659786C2 (ru) 2012-05-15 2018-07-04 Кансер Ресёрч Текнолоджи Лимитед 5-[[4-[[морфолин-2-ил]метиламино]-5-(трифторметил)-2-пиридил]амино]пиразин-2-карбонитрил, его терапевтические применения
WO2014153464A2 (en) 2013-03-20 2014-09-25 Lorus Therapeutics Inc. 2-substituted imidazo[4,5-d]phenanthroline derivatives and their use in the treatment of cancer
CN103288803B (zh) * 2013-05-17 2017-10-31 郎恒元 苯并咪唑酰胺类化合物及其制备方法和应用
ES2775579T3 (es) 2013-10-04 2020-07-27 Aptose Biosciences Inc Composiciones para el tratamiento del cáncer
CN104194778B (zh) * 2014-09-25 2016-03-30 黑龙江大学 磷氧基团修饰n-苯基-苯并咪唑电子传输材料、合成方法及电致磷光器件的制备方法
ES2973850T3 (es) 2016-09-20 2024-06-24 Centre Leon Berard Derivados del benzoimidazol como agentes anticancerígenos
CN111417395A (zh) 2017-10-30 2020-07-14 艾普托斯生物科学公司 用于治疗癌症的芳基咪唑
MA52954A (fr) 2018-06-21 2021-04-28 Cellestia Biotech Ag Procédé pour la fabrication d'aminoéthers de diaryle et sels de chlorhydrate d'aminoéthers de diaryle
CA3134791A1 (en) * 2019-04-10 2020-10-15 Cellestia Biotech Ag Inhibitors of notch signalling pathway and use thereof in treatment of cancers
US20220304984A1 (en) * 2019-06-12 2022-09-29 Vanderbilt University Amino acid transport inhibitors and the uses thereof
TW202204348A (zh) 2020-04-07 2022-02-01 美商西爾拉癌症醫學公司 Chk1抑制劑之合成方法
KR20240068737A (ko) 2021-09-27 2024-05-17 테른스 파마슈티칼스, 인크. Glp-1r 효능제로서의 벤즈이미다졸 카복실산
AU2022375634A1 (en) 2021-10-25 2024-06-06 Terns Pharmaceuticals, Inc. Compounds as glp-1r agonists
KR20240150488A (ko) 2022-02-23 2024-10-15 테른스 파마슈티칼스, 인크. Glp-1r 작용제로서의 화합물
US20240398794A1 (en) 2023-04-07 2024-12-05 Terns Pharmaceuticals, Inc. COMBINATIONS OF GLP-1R AND THRß AGONISTS AND METHODS OF USE THEREOF
CN119552166B (zh) * 2024-11-29 2025-10-17 中国药科大学 一种parp1/cdk6双靶点抑制剂及其制备方法与应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346575A1 (de) 1983-12-23 1985-07-04 Dr. Karl Thomae Gmbh, 7950 Biberach Neue benzimidazole, ihre herstellung und diese verbindungen enthaltende arzneimittel
LU85544A1 (fr) 1984-09-19 1986-04-03 Cird Derives heterocycliques aromatiques,leur procede de preparation et leur application dans les domaines therapeutique et cosmetique
DE3522230A1 (de) 1985-06-21 1987-01-02 Thomae Gmbh Dr K Neue 2-arylimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
GB9108279D0 (en) * 1991-04-18 1991-06-05 Ucb Sa A method of preparing 1h-benzimidazoles
US5821258A (en) 1994-12-27 1998-10-13 Mitsui Chemicals, Inc. Phenylbenzimidazole derivatives
JP2000516611A (ja) 1996-08-14 2000-12-12 ワーナー―ランバート・コンパニー Mcp―1アンタゴニストとしての2―フェニルベンズイミダゾール誘導体
US5942532A (en) 1997-09-05 1999-08-24 Ortho Pharmaceutical Corporation 2-substituted phenyl-benzimidazole antibacterial agents
ATE355841T1 (de) * 1997-12-13 2007-03-15 Bristol Myers Squibb Co Verwendung von pyrazolo ( 3,4-b) pyridin als cyclin-abhängige kinase hemmer
RU2236220C2 (ru) 1998-05-22 2004-09-20 Аванир Фармасьютикэлз Аналоги бензимидазола в качестве понижающих регуляторов ige
DE59911249D1 (de) * 1998-11-03 2005-01-13 Abbott Gmbh & Co Kg Substituierte 2-phenylbenzimidazole, deren herstellung und anwendung
GB9914825D0 (en) * 1999-06-24 1999-08-25 Smithkline Beecham Spa Novel compounds
YU54202A (sh) * 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
GB0007934D0 (en) * 2000-03-31 2000-05-17 Darwin Discovery Ltd Chemical compounds
DE10026435A1 (de) * 2000-05-29 2002-04-18 Osram Opto Semiconductors Gmbh Kalzium-Magnesium-Chlorosilikat-Leuchtstoff und seine Anwendung bei Lumineszenz-Konversions-LED
CN1203557C (zh) * 2000-05-29 2005-05-25 电灯专利信托有限公司 基于发光二极管的发射白光的照明设备
WO2001098465A1 (en) 2000-06-21 2001-12-27 Chugai Seiyaku Kabushiki Kaisha Cds1 GENE-KNOCKOUT CELLS AND MOUSE AND UTILIZATION THEREOF
US20060027785A1 (en) * 2004-08-04 2006-02-09 Intematix Corporation Novel silicate-based yellow-green phosphors
US7311858B2 (en) * 2004-08-04 2007-12-25 Intematix Corporation Silicate-based yellow-green phosphors
US20060279196A1 (en) * 2005-06-02 2006-12-14 Wei-Jen Hsu White LED
JP2007231250A (ja) * 2006-02-02 2007-09-13 Nichia Chem Ind Ltd 蛍光体及びそれを用いた発光装置

Also Published As

Publication number Publication date
US7271261B2 (en) 2007-09-18
BR0206161A (pt) 2005-02-01
ES2292812T3 (es) 2008-03-16
EP1435947B1 (en) 2007-08-15
US20030176438A1 (en) 2003-09-18
ZA200305533B (en) 2004-10-18
NO20032759D0 (no) 2003-06-17
EP1435947A1 (en) 2004-07-14
US20080009493A1 (en) 2008-01-10
WO2003032984A8 (en) 2003-11-20
RS50939B (sr) 2010-08-31
US7504414B2 (en) 2009-03-17
CA2464000A1 (en) 2003-04-24
CA2464000C (en) 2011-04-19
DE60221866T2 (de) 2008-05-29
DE60221866D1 (de) 2007-09-27
NO20032759L (no) 2003-08-18
JP2005506349A (ja) 2005-03-03
YU49203A (sh) 2006-05-25
WO2003032984A1 (en) 2003-04-24
ATE369854T1 (de) 2007-09-15

Similar Documents

Publication Publication Date Title
JP4637481B2 (ja) Cds1/chk2阻害剤および癌治療における化学療法または放射線療法の補助剤としての2−フェニルベンズイミダゾールおよびイミダゾ−[4,5]−ピリジン
EP1268478B1 (en) Phenyl-substituted imidazopyridines
DE60126286T2 (de) Substituierte pyrazole
US20070043057A1 (en) Lonidamine analogs
ES2325477T3 (es) Indoles sustituidos por fenilo como antagonistas del receptor de histamina h3.
US20070015771A1 (en) Lonidamine analogs
JP2006520796A (ja) ヒストンデアセチラーゼインヒビター
GB2432834A (en) Selective Kinase Inhibitors
KR20070113207A (ko) 신규한 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물
FI90235B (fi) Menetelmä eläinlääketieteellisesti käyttökelpoisten -aryyli-4-(4,5-dihydro-3,5-diokso-1,2,4-triatsin-2(3H)-yyli)bentseeniasetonitriilien valmistamiseksi
US9096531B2 (en) Fused imidazole derivative
WO2001074813A2 (en) METHOD FOR USING 2- OR 3-ARYL SUBSTITUTED IMIDAZO[1,2-a] PYRIDINES AS H3 ANTAGONISTS
DE60101906T2 (de) Phenyl-substituierte indolizinderivate und deren verwendung als histamin h3 liganden
RU2286343C2 (ru) Замещенные пиразолы
JP4726235B2 (ja) 癌の処置のためのチェックポイントキナーゼcds1(chk2)インヒビターとしての2−フェニル−ベンズイミダゾールおよび2−フェニル−イミダゾ−‘4,5!−ピリジン誘導体
JP2007523922A (ja) チアジアゾールウレア誘導体の使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051018

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051018

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20080427

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090707

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20090708

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091007

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091015

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100107

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100610

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20100714

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20101109

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20101124

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131203

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4637481

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term